CME opportunity

Highlights of ASH 2021

Friday, February 25, 2022
Attend Live or Virtually
Fairmont Hotel
510 Market Street
Pittsburgh, PA

Jointly provided by
Allegheny General Hospital and
Allegheny Health Network Cancer Institute
Division of Hematology and Cellular Therapy
West Penn Hospital
Pittsburgh, PA

This meeting is not sponsored, sanctioned by, or part of the Annual Meeting of the American Society of Hematology.

CME accreditation

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint Provisionship of Allegheny General Hospital and AHN Cancer Institute West Penn Hospital. Allegheny General Hospital is accredited by the ACCME to provide continuing medical education for physicians. Allegheny General Hospital designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credit™ are acceptable for continuing medical education requirements for recertification.

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Non-Physicians: Allegheny General Hospital certifies participation in this educational activity.

Registration

Register at cme.ahn.org.

Physicians: $125
AHN physicians: $80
Nurses and others: $65
AHN nurses and others: $45
Virtual attendees: $45
Residents and fellows: Complimentary

AHN and Highmark employees

Log in using your AHN or Highmark email and network password. Once logged in, make sure you complete your profile to earn and track your credit.

Visitors

To create a new visitor account:

1. Click Visitor Login at the top right corner of the homepage, then complete the required fields.
2. Once you are logged in, click Courses, type in Highlights of ASH 2021, then click Register.
Course overview

The field of hematology has been rapidly evolving. This continuing medical education activity will cover new developments in the diagnosis and treatment of malignant and nonmalignant hematological disorders, as presented at the 2021 Annual Meeting of the American Society of Hematology (ASH). In this one-day course, faculty will share the latest updates in myeloid malignancies, lymphoma, leukemia, multiple myeloma, coagulation disorders, and stem cell transplantation. Through presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for hematological malignancies and blood disorders and how these new therapies can be integrated into daily practice.

Target audience

This conference is intended for primary care physicians, hematologists and medical oncologists, fellows, residents, CRNPs, PAs, nurses, and all other health care providers.

Objectives

- Discuss the cutting-edge data presented at the 2021 Annual Meeting of the ASH.
- Identify updates in molecular abnormalities that can be utilized in the diagnosis, prognosis, risk stratification, and therapy selection for patients with myeloid malignancies.
- Discuss and assess the relevant clinical trial data in clinical practice, which has the potential to improve outcomes in patients with malignant hematologic disorders including non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma.
- Review the updates in sequencing strategies in the era of novel immunotherapies, CAR T-cell therapy, targeted therapies, and stem cell transplantation.
- Discuss the latest advances in coagulation and platelet disorders.

Agenda

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/15 – 8 a.m.</td>
<td>Registration, breakfast, and visit exhibits</td>
<td></td>
</tr>
<tr>
<td>8 – 8:15 a.m.</td>
<td>Welcome and introductions</td>
<td></td>
</tr>
<tr>
<td>8:15 – 9 a.m.</td>
<td>Salman Fazel, MD</td>
<td></td>
</tr>
<tr>
<td>9 – 9:45 a.m.</td>
<td>Platelet disorders</td>
<td></td>
</tr>
<tr>
<td>9:45 – 10 a.m.</td>
<td>Shruti Chaturvedi, MD, MSCi</td>
<td></td>
</tr>
<tr>
<td>10 – 10:45 a.m.</td>
<td>Coagulation disorders</td>
<td></td>
</tr>
<tr>
<td>10:45 – 11:30 a.m.</td>
<td>MDS/AML updates</td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:30 p.m.</td>
<td>Hotly Corraway, MD, MBA</td>
<td></td>
</tr>
<tr>
<td>12:30 – 1:15 p.m.</td>
<td>Multiple myeloma</td>
<td></td>
</tr>
<tr>
<td>1:15 – 1:45 p.m.</td>
<td>Bino Dhalak, MD</td>
<td></td>
</tr>
<tr>
<td>2:15 – 3 p.m.</td>
<td>Enrica Marchi, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>3 p.m.</td>
<td>Evaluation/adjournment</td>
<td></td>
</tr>
</tbody>
</table>

Course director

Salman Fazel, MD
Course Director, Assistant Professor of Medicine, Drexel University School of Medicine, Director, Cell Transplantation Program, AHN Cancer Institute, West Penn Hospital.

Invited faculty

- Hotly Corraway, MD, MBA
  Director, Leukemia Program, Vice Chair, Strategy and Enterprise Development, Taussig Cancer Institute, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Hematology-Oncology, Taussig Cancer Institute, Cleveland, OH.
- Shruti Chaturvedi, MD, MSCi
  Assistant Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
- Bino Dhalak, MD
  Associate Professor of Medicine, Medical College of Wisconsin Division of Hematology/Oncology, Milwaukee, WI.
- Aaron T. Gerds, MD, MS
  Associate Professor of Medicine, Hematology and Medical Oncology, Deputy Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute, Medical Director, Case Comprehensive Cancer Center Clinical Research Office, Cleveland, OH.
- Allyson Pishko, MD
  Assistant Professor, Hematology/Oncology, University of Pennsylvania Penn Blood Disorders Center, Philadelphia, PA.
- Nirav Shah, MD
  Assistant Professor of Medicine, Lymphoma/BMT Program, Medical College of Wisconsin, Milwaukee, WI.
- Francisco J. Hernandez-Illizaliturri, MD
  Chief, Lymphoma Section, Professor of Medicine, Department of Medicine, Head, Lymphoma Translational Research Lab, Associate Professor of Immunology, Department of Immunology, Roswell Park Comprehensive Cancer Center, Clinical Professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY.
- Enrica Marchi, MD, PhD
  Assistant Professor of Medicine, Microbiology, Immunology, and Cancer Biology, Co-Director, Program for T-Cell Lymphoma Research Division of Hematology-Oncology, Department of Medicine, University of Virginia, Charlottesville, VA.
- Aaron T. Gerds, MD, MS
  Associate Professor of Medicine, Hematology and Medical Oncology, Associate Professor of Medicine, Hematology-Oncology, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.
- Allyson Pishko, MD
  Assistant Professor, Hematology/Oncology, University of Pennsylvania Penn Blood Disorders Center, Philadelphia, PA.
- Nirav Shah, MD
  Assistant Professor of Medicine, Lymphoma/BMT Program, Medical College of Wisconsin, Milwaukee, WI.

Disclosure of Significant Relationships with Relevant Commercial Companies

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest (e.g., ownership of stock, honorarium, or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).